Loading…
Valion Bio, Inc. is projected to decline to $0.4366 by 2027, a -14% move from its current price of $0.509. VBIO is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $0.4832 | $0.5089 | $0.536 | -0.02% |
| Jul 13 | $0.4729 | $0.5088 | $0.5475 | -0.03% |
| Jul 14 | $0.4651 | $0.5087 | $0.5565 | -0.05% |
| Jul 15 | $0.4586 | $0.5087 | $0.5642 | -0.07% |
| Jul 16 | $0.453 | $0.5086 | $0.571 | -0.08% |
| Jul 17 | $0.4479 | $0.5085 | $0.5773 | -0.10% |
| Jul 18 | $0.4433 | $0.5084 | $0.5831 | -0.12% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4433 | $0.5084 | $0.5831 | -0.12% |
| Week 2 | $0.4183 | $0.5078 | $0.6164 | -0.23% |
| Week 3 | $0.4001 | $0.5072 | $0.6431 | -0.35% |
| Week 4 | $0.3852 | $0.5066 | $0.6664 | -0.47% |
| Week 5 | $0.3725 | $0.506 | $0.6875 | -0.58% |
| Week 6 | $0.3613 | $0.5054 | $0.707 | -0.70% |
| Week 7 | $0.3513 | $0.5048 | $0.7255 | -0.82% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Valion Bio, Inc. is a healthcare company described as a late-stage biopharmaceutical firm. Its lead drug candidate Entolimod is a TLR5 agonist that is in late-stage development to treat acute radiation syndrome.
The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it offers CDMO services. The company was formerly known as Tivic Health Systems, Inc.
and changed its name to Valion Bio, Inc. in April 2026. The company was incorporated in 2016 and is based in San Antonio, Texas.
Valion Bio, Inc. (VBIO) currently trades at $0.4989 and has a market cap of $1.6M, with a rank of 5332. The stock’s near-term outlook is reflected in the 2026 forecast, which shows a min and avg price of $0.4989 and a max of $0.6997 with an ROI of 0 and a NEUTRAL sentiment. The stock operates within the Healthcare sector.
A major floor 42.7% below — a decisive break under it would weaken the trend.
The nearest floor, 3.7% below — buyers have tended to step in here.
The nearest ceiling, 56.6% above — a clean break opens room to run.
A major ceiling 175.0% above — clearing it would confirm fresh momentum.
Key VBIO support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VBIO market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.5042 | Buy | $0.5064 | Buy |
| MA 10 | $0.5164 | Sell | $0.5184 | Sell |
| MA 20 | $0.5351 | Sell | $0.562 | Sell |
| MA 50 | $0.7405 | Sell | $0.7016 | Sell |
| MA 100 | $0.8485 | Sell | $0.9244 | Sell |
| MA 200 | $1.42 | Sell | $2.17 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 36.57 | Neutral |
| Stoch RSI (14) | 70.12 | Neutral |
| CCI (20) | -66.90 | Neutral |
| Williams %R (14) | -78.16 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | -4.50 | Sell |
| Bollinger %B (20,2) | 0.28 | Neutral |
| Stochastic %K (14) | 21.84 | Neutral |
| TRIX (15) | -1.66 | Sell |
| Awesome (5,34) | -0.13 | Sell |
| Ultimate (7,14,28) | 42.91 | Neutral |
| Momentum (10) | -0.07 | Sell |
| Aroon Osc (25) | -72.00 | Sell |
| Hull MA (9) | 0.50 | Buy |
| ADX (14) | 27.45 | Sell |
| ATR (14) | 0.03 | Info |
The 30-day technical picture is NEUTRAL with RSI14 at 30. They show SMA50 at $0.81 and SMA200 at $1.48, indicating potential resistance above the current price. The stock has support at $0.499 and resistance at $0.879, with a 30-day range from $0.3387 to $0.7349.
Annualized volatility is 100%, underscoring the delicate short-term price movements around the current level.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.49 | $0.509 | $0.709 | 0% | Neutral | |
| $0.3186 | $0.4366 | $0.6464 | -14% | Neutral | |
| $0.3066 | $0.4455 | $0.7018 | -12% | Neutral | |
| $0.3327 | $0.5082 | $0.8396 | 0% | Neutral | |
| $0.4019 | $0.6423 | $1.10 | +26% | Bullish | |
| $0.4278 | $0.7132 | $1.27 | +40% | Bullish | |
| $0.3367 | $0.5845 | $1.07 | +15% | Neutral | |
| $0.3271 | $0.5901 | $1.11 | +16% | Neutral | |
| $0.3335 | $0.6247 | $1.20 | +23% | Bullish | |
| $0.2661 | $0.5171 | $1.02 | +2% | Neutral | |
| $0.3376 | $0.7502 | $1.62 | +47% | Bullish | |
| $0.7968 | $1.77 | $4.07 | +248% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.49 | $0.509 | $0.629 | +0.00% |
| August 2026 | $0.4077 | $0.4933 | $0.6212 | -3.09% |
| September 2026 | $0.4088 | $0.5013 | $0.6441 | +1.62% |
| October 2026 | $0.4405 | $0.5466 | $0.7143 | +9.04% |
| November 2026 | $0.441 | $0.5527 | $0.7324 | +1.11% |
| December 2026 | $0.4176 | $0.5283 | $0.709 | -4.42% |
Click any year to see its month-by-month VBIO forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Valion Bio, Inc.'s 2026 outlook centres on $0.509, within a $0.49 to $0.709 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, VBIO could reach as high as $0.6464, with a base case around $0.4366 and support toward $0.3186 — roughly -14% from $0.509. Price action looks broadly range-bound.
Expect VBIO to range from $0.3066 to $0.7018 through 2028. The $0.4455 average target implies a -12% move from current prices. That is up +2% on the projected 2027 average. A consolidation phase looks the most probable path here.
The VBIO price prediction for 2029 points to an average of $0.5082 (low $0.3327, high $0.8396) — a potential decline of 0% on today's $0.509. Price action looks broadly range-bound.
In 2030, VBIO is projected to trade between $0.4019 and $1.10, averaging $0.6423 — a potential gain of +26% from today's $0.509. That is up +26% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Valion Bio, Inc.'s 2031 outlook centres on $0.7132, within a $0.4278 to $1.27 range. That is up +11% on the projected 2030 average. That marks a +40% change versus current levels. Momentum favours further upside here.
By 2032, VBIO could reach as high as $1.07, with a base case around $0.5845 and support toward $0.3367 — roughly +15% from $0.509. A consolidation phase looks the most probable path here.
Expect VBIO to range from $0.3271 to $1.11 through 2033. The $0.5901 average target implies a +16% move from current prices. That is up +1% on the projected 2032 average. Price action looks broadly range-bound.
The VBIO price prediction for 2034 points to an average of $0.6247 (low $0.3335, high $1.20) — a potential gain of +23% on today's $0.509. Buyers look set to stay in control over this stretch.
In 2035, VBIO is projected to trade between $0.2661 and $1.02, averaging $0.5171 — a potential gain of +2% from today's $0.509. That is -17% versus the projected 2034 average. Price action looks broadly range-bound.
Valion Bio, Inc.'s 2040 outlook centres on $0.7502, within a $0.3376 to $1.62 range. That is up +45% on the projected 2035 average. That marks a +47% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, VBIO could reach as high as $4.07, with a base case around $1.77 and support toward $0.7968 — roughly +248% from $0.509. Momentum favours further upside here.
Investing $1,000 in VBIO today (≈ 1,964.636542 VBIO) could be worth
$3,478.52
+$2,478.52 (+248%) by 2050 · US Dollar
Based on the average projected VBIO price of $1.77 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VBIOwould be worth at today's price.
$1,000 invested in VBIO on Jul 10, 2025 (≈ 235.294118 VBIO) would be worth
$119.76
-$880.24 (-88.0%) today · 0.12× · US Dollar
Based on a VBIO entry price of $4.25 vs. today's $0.509.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.499 | $1,020.04 | +2.0% |
| 1 month ago | $0.797 | $638.64 | -36.1% |
| 3 months ago | $0.931 | $546.72 | -45.3% |
| 6 months ago | $1.38 | $368.84 | -63.1% |
| 1 year ago | $4.25 | $119.76 | -88.0% |
| All time (4.7y) ago | $8,823 | $0.06 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VBIO forecast.
Our base-case forecast reaches $1.00 around 2050.
Implied market cap at $1.00: $3.2M
The multi-year forecast shows a mixed path before a stronger uptrend later. For 2027 and 2028, the average prices are $0.4257 and $0.4188 with ROIs of -14.7 and -16.1, respectively, signaling bearish years before a rebound. By 2029 the average is $0.503 with a modest ROI of 0.8, followed by a bullish run starting in 2030 with an average of $0.6459 and ROI of 29.5, and in 2031 with an average of $0.6961 and ROI of 39.5.
The years 2032 to 2035 show cautious gains (2032: ROI 15; 2033: ROI 17.2; 2034: ROI 20; 2035: ROI -1.5) with average prices around $0.57–$0.60. The trajectory improves markedly toward 2040 (avg $0.7142, ROI 43.2) and projects further upside by 2050 (avg $1.77, ROI 255.3, max $4.08) with a bullish sentiment. These are estimates and not guarantees, and actual results may vary.
Tap a question to reveal the answer.
The 2030 forecast shows an avg of $0.6459 with a min of $0.3988 and a max of $1.12, and an ROI of 29.5 with a BULLISH sentiment.
Forecasts indicate a mix of risk and upside. 2027 and 2028 show negative ROIs (-14.7 and -16.1), but years 2030 onward show bullish upside (2030 ROI 29.5; 2031 ROI 39.5; 2040 ROI 43.2; 2050 ROI 255.3). These are estimates and not guarantees.
Yes. The 2030 max is $1.12, the 2031 max is $1.25, the 2040 max is $1.57, and the 2050 max is $4.08.
Sentiment is NEUTRAL with RSI14 at 30. The SMA indicators are SMA50 at $0.81 and SMA200 at $1.48. The price has support at $0.499 and resistance at $0.879, with a 30-day range of $0.3387 to $0.7349.
VBIO’s current price is $0.4989 and its market cap is $1.6M, with a rank of 5332.
Valion Bio, Inc. Community Discussion
0Share your Valion Bio, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.